cimb-logo

Journal Browser

Journal Browser

Novel Pharmacological Strategies and Molecular Mechanisms in Nonclinical Research

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 101

Special Issue Editor


E-Mail Website
Guest Editor
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
Interests: pharmacology; pharmacotherapy; non-clinical studies in vivo; animal models of disease; inflammation; inflammatory bowel disease

Special Issue Information

Dear Colleagues,

The Special Issue "Novel Pharmacological Strategies and Molecular Mechanisms in Nonclinical Research" aims to explore innovative advances in pharmacology, focusing on the molecular underpinnings that drive drug efficacy and safety in nonclinical models. As the complexity of disease biology becomes increasingly evident, the development of targeted pharmacological interventions requires an in-depth understanding of their molecular and cellular pathways. This Special Issue seeks to gather original research and systematic reviews on novel drug targets, signalling cascades, receptor–drug interactions, gene expression modulation, and molecular biomarkers predictive of therapeutic response.

Particular emphasis will be placed on studies employing in vivo models to uncover mechanistic insights into drug action. Contributions may also include innovative drug delivery approaches, pharmacological structure–activity relationships, and pharmacogenomic strategies. By bridging molecular mechanisms with pharmacological innovation, this Special Issue aims to provide a comprehensive overview of how molecular-level research can be integrated with preclinical development to guide the rational design of next-generation therapeutics, enhancing their translational potential.

Researchers from pharmacology, molecular biology, and related disciplines are invited to contribute to this Special Issue,  which aims to promote interdisciplinary dialogue and accelerate the bench-to-bedside transition of novel pharmacological strategies.

Dr. Vanessa Mateus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular pharmacology
  • drug targets
  • signal transduction pathways
  • nonclinical models
  • receptor-ligand interactions
  • pharmacogenomics
  • preclinical drug development
  • gene expression modulation
  • mechanism of action
  • translational pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2282 KB  
Article
Activation of Angiogenic TGF-β1 by Salbutamol Enhances Wound Contraction and Improves Healing in a Streptozotocin-Induced Diabetic Rat Model
by Promise M. Emeka, Abdulaziz K. Al Mouslem, Hussien Almutawa, Malek Albandri, Hussain Alhmoud, Mohammed Alhelal, Zakaria Alhassan and Abdullah Alhamar
Curr. Issues Mol. Biol. 2025, 47(10), 820; https://doi.org/10.3390/cimb47100820 - 3 Oct 2025
Abstract
Wound healing is impaired under diabetic conditions due to reduced angiogenesis, thereby increasing the risk of wound-healing complications. Studies have shown that inhibition of α- and β-adrenoceptors delays wound healing. This study investigates the effects of topical salbutamol (TS) on STZ-induced diabetic wound [...] Read more.
Wound healing is impaired under diabetic conditions due to reduced angiogenesis, thereby increasing the risk of wound-healing complications. Studies have shown that inhibition of α- and β-adrenoceptors delays wound healing. This study investigates the effects of topical salbutamol (TS) on STZ-induced diabetic wound healing in rats. The rats were divided into two initial groups: non-diabetic and diabetic. Diabetes mellitus was induced in the second group with STZ (65 mg/kg). Excision wounds were inflicted on the dorsal thoracic region, 1–1.5 cm away from the vertebral column on either side, following anesthesia on all groups. Group 2 was subdivided into untreated diabetic wounds, low-dose-TS-treated diabetic wounds (6.25 mg/mL), medium-dose-TS-treated diabetic wounds (12.5 mg/mL), and high-dose-TS-treated diabetic wounds (25 mg/mL), and were monitored for 14 days. Percentage wound contraction and the time required for complete wound closure were observed and recorded. In addition, oxidative stress and inflammatory markers such as NO, CRP, MPO, TGF-β1, TNF-α, IL-6, IL-1β, NO, and hexosamine were estimated in wound exudates and tissue over 14 days. TS treatment resulted in 100% wound contraction in all treated wounds within 14 days compared to untreated non-diabetic and diabetic wounds. Increased NO, TGF-β1, and hexosamine activity was observed in TS-treated wounds when compared to untreated diabetic wounds. In addition, TS treatment decreased the activity of IL-1β, TNF-α, IL-6, CRP, and MPO, all of which were elevated in the untreated diabetic wounds. The current study shows that the application of TS significantly improved diabetic wound contraction and aided the healing process. Angiogenic markers, such as TGF-β1 and NO, were prominently increased, supporting the role of sympathetic nerve stimulation in angiogenesis. Full article
Show Figures

Figure 1

Back to TopTop